209 related articles for article (PubMed ID: 7728354)
1. Hypoxanthine-guanine phosphoribosyltransferase as a therapeutic target in protozoal infections.
Ullman B; Carter D
Infect Agents Dis; 1995 Mar; 4(1):29-40. PubMed ID: 7728354
[TBL] [Abstract][Full Text] [Related]
2. Molecular and biochemical studies on the hypoxanthine-guanine phosphoribosyltransferases of the pathogenic haemoflagellates.
Ullman B; Carter D
Int J Parasitol; 1997 Feb; 27(2):203-13. PubMed ID: 9088991
[TBL] [Abstract][Full Text] [Related]
3. Development of a bacterial screen for novel hypoxanthine-guanine phosphoribosyltransferase substrates.
Shivashankar K; Subbayya IN; Balaram H
J Mol Microbiol Biotechnol; 2001 Oct; 3(4):557-62. PubMed ID: 11545274
[TBL] [Abstract][Full Text] [Related]
4. Altering the purine specificity of hypoxanthine-guanine-xanthine phosphoribosyltransferase from Tritrichomonas foetus by structure-based point mutations in the enzyme protein.
Munagala NR; Wang CC
Biochemistry; 1998 Nov; 37(47):16612-9. PubMed ID: 9843428
[TBL] [Abstract][Full Text] [Related]
5. Hypoxanthine-guanine phosphoribosyltransferase from Mycobacterium tuberculosis H37Rv: cloning, expression, and biochemical characterization.
Biazus G; Schneider CZ; Palma MS; Basso LA; Santos DS
Protein Expr Purif; 2009 Aug; 66(2):185-90. PubMed ID: 19362594
[TBL] [Abstract][Full Text] [Related]
6. Hypoxanthine-Guanine Phosphoribosyltransferase Is Dispensable for Mycobacterium smegmatis Viability.
Knejzlík Z; Herkommerová K; Hocková D; Pichová I
J Bacteriol; 2020 Feb; 202(5):. PubMed ID: 31818925
[TBL] [Abstract][Full Text] [Related]
7. Rational design of novel antimicrobials: blocking purine salvage in a parasitic protozoan.
Somoza JR; Skillman AG; Munagala NR; Oshiro CM; Knegtel RM; Mpoke S; Fletterick RJ; Kuntz ID; Wang CC
Biochemistry; 1998 Apr; 37(16):5344-8. PubMed ID: 9548915
[TBL] [Abstract][Full Text] [Related]
8. Purine and pyrimidine transport in pathogenic protozoa: from biology to therapy.
de Koning HP; Bridges DJ; Burchmore RJ
FEMS Microbiol Rev; 2005 Nov; 29(5):987-1020. PubMed ID: 16040150
[TBL] [Abstract][Full Text] [Related]
9. Cloning and expression of the hypoxanthine-guanine phosphoribosyltransferase gene from Trypanosoma brucei.
Allen TE; Ullman B
Nucleic Acids Res; 1993 Nov; 21(23):5431-8. PubMed ID: 8265360
[TBL] [Abstract][Full Text] [Related]
10. Unusual substrate specificity of a chimeric hypoxanthine-guanine phosphoribosyltransferase containing segments from the Plasmodium falciparum and human enzymes.
Sujay Subbayya IN; Sukumaran S; Shivashankar K; Balaram H
Biochem Biophys Res Commun; 2000 Jun; 272(2):596-602. PubMed ID: 10833458
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of Thermoanaerobacter tengcongensis hypoxanthine-guanine phosphoribosyl transferase L160I mutant--insights into inhibitor design.
Chen Q; You D; Liang Y; Su X; Gu X; Luo M; Zheng X
FEBS J; 2007 Sep; 274(17):4408-15. PubMed ID: 17662107
[TBL] [Abstract][Full Text] [Related]
12. Cloning, characterization and preliminary crystallographic analysis of Leishmania hypoxanthine-guanine phosphoribosyltransferase.
Monzani PS; Alfonzo JD; Simpson L; Oliva G; Thiemann OH
Biochim Biophys Acta; 2002 Jul; 1598(1-2):3-9. PubMed ID: 12147338
[TBL] [Abstract][Full Text] [Related]
13. [Clinical spectrum of hypoxanthine-guanine phosphoribosyltransferase deficiency: study of 12 cases].
García Puig J; Mateos FA; Jiménez ML; Arcas J; Miranda ME; Oríz Vázquez J
Med Clin (Barc); 1994 May; 102(18):681-7. PubMed ID: 8028417
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of Leishmania tarentolae hypoxanthine-guanine phosphoribosyltransferase.
Monzani PS; Trapani S; Thiemann OH; Oliva G
BMC Struct Biol; 2007 Sep; 7():59. PubMed ID: 17894860
[TBL] [Abstract][Full Text] [Related]
15. [Cloning, expression and characterization of the hypoxanthine-guanine phosphoribosyltransferase mutants from T. tengcongensis].
You DL; Qu H; Chen Q; Xing Y; Gu XC; Luo M
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):853-8. PubMed ID: 12958660
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of purine N9-[2-hydroxy-3-O-(phosphonomethoxy)propyl] derivatives and their side-chain modified analogs as potential antimalarial agents.
Krečmerová M; Dračínský M; Hocková D; Holý A; Keough DT; Guddat LW
Bioorg Med Chem; 2012 Feb; 20(3):1222-30. PubMed ID: 22249123
[TBL] [Abstract][Full Text] [Related]
17. The cell cycle of parasitic protozoa: potential for chemotherapeutic exploitation.
Hammarton TC; Mottram JC; Doerig C
Prog Cell Cycle Res; 2003; 5():91-101. PubMed ID: 14593704
[TBL] [Abstract][Full Text] [Related]
18. Antiparasitic chemotherapy: tinkering with the purine salvage pathway.
Datta AK; Datta R; Sen B
Adv Exp Med Biol; 2008; 625():116-32. PubMed ID: 18365663
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of hypoxanthine-guanine phosphoribosyltransferase by acyclic nucleoside phosphonates: a new class of antimalarial therapeutics.
Keough DT; Hocková D; Holý A; Naesens LM; Skinner-Adams TS; Jersey Jd; Guddat LW
J Med Chem; 2009 Jul; 52(14):4391-9. PubMed ID: 19527031
[TBL] [Abstract][Full Text] [Related]
20. Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
Keough DT; Skinner-Adams T; Jones MK; Ng AL; Brereton IM; Guddat LW; de Jersey J
J Med Chem; 2006 Dec; 49(25):7479-86. PubMed ID: 17149876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
